Our study also highlighted a new regulatory mechanism of m6A mRNA export, which closely impacts BC doxorubicin resistance in vitro and in vivo, and provided a rationale for targeting the PCAT6‐ISG15‐hnRNPA2B1‐FGFR1 signaling axis as a potential therapeutic strategy in BC. Here, HNRNPA2B1 is linked to breast cancer.